Tuberculosis (TB), as an infectious disease is caused by
Members of MTBC are usually transmitted to susceptible persons through airborne means such as coughing, sneezing, or speaking by patients suffering from infectious tuberculosis (Churchyard et al. 2016). The successful establishment of an infection in the lungs is influenced by various factors such as phagocytosis of the bacilli, their intracellular multiplication, latency, and active lung infection (Banuls et al. 2015). However, there is no clear evidence that NTMs are transmitted from either person to person or from animals to people. Therefore, the transmission of NTMs is probably through individual contacts with the source of infection (Churchyard et al. 2016).
Since the treatment of
Treatment and prophylaxis of tuberculosis differ from most other bacterial infections. In general, patients should receive multiple antibiotic treatments for at least 6 to 9 months (Ozmen et al. 2017). The World Health Organization (WHO) recommends the combined use of 1st-line drugs in the initial treatment of tuberculosis. However, anti-tuberculosis drug resistance remains a significant problem. Of the primary anti-tuberculosis drugs, isolates showing at least isoniazid (INH) and rifampin (RIF) resistance are defined as Multiple Drug-Resistant Tuberculosis (MDR-TB) (WHO 2019).
In this study, we aimed to document
Ethical approval was provided from the Ethics Committee of Medical School, Bezmialem University, Istanbul, Turkey (10.09.2019/16–302).
Our facility is a 700-bed academic hospital providing tertiary health care in Istanbul city centre, and 7,480 patients with pre-diagnosis of tuberculosis admitted to Bezmialem University Medical Faculty Hospital between September 2015 and June 2019 were included in the study. Between the dates indicated, 7,480 clinical specimens were sent to the Clinical Microbiology Laboratory with a preliminary diagnosis of tuberculosis. Two hundred seventy-eights of these samples were positive for
Homogenization and decontamination of sputum, bronchoalveolar lavage (BAL), fasting gastric juice, urine, and abscess materials were performed according to published guidelines. Sterile body fluids such as cerebrospinal fluid (CSF), peritoneal and pleural fluid, and tissue samples were tested without decontamination. N-acetyl-L-cysteine-4% sodium hydroxide-1.47% sodium citrate (NALC-NaOH) method was used for decontamination and homogenization of the samples. Five to ten ml of each clinical sample was mixed with an equal volume of NALC-NaOH solution. The mixture was transferred to tubes and vortexed for not more than 30 seconds. The tubes containing the mixture were allowed to stand at room temperature for 15 minutes. Fifty ml of phosphate buffer (0.067 M, pH = 6.8) was added to each tube containing the mixture, and the tubes were centrifuged at 3,000 g for 15 minutes. The resulting precipitates were diluted with 1–2 ml of phosphate buffer (pH = 6.8), and smears were prepared from these precipitates. The smears were stained by Erlich-Ziehl-Neelsen (EZN) (GBL Rose Biology Laboratory, Istanbul) method and examined microscopically under immersion oil.
For the liquid culture of mycobacteria, a
Simultaneous cultivation of the samples on solid media was carried out on Löwenstein-Jensen (LJ) slants (Becton Dickinson, USA). LJ tubes were evaluated daily for 42 days, and the cultures were terminated by 42nd day if no colonies observed. The presence of acid-resistant bacilli was screened by EZN staining from positive cultures.
In the study,
In 278 (3.7%) of 7,480 clinical specimens from patients with suspected tuberculosis, one type of
The type of specimens from which MTBC’s were isolated was as follows: 198 respiratory tract samples (sputum, BAL and tracheal aspirate), 29 tissue specimens (lymph node biopsy, etc.), 22 sterile body fluids (pleura, peritoneum, CSF), 11 fasting gastric fluid, 11 abscesses, and seven urine samples.
In our study, the AFB positivity was 1.4% (104/7,480), and the culture positivity (LJ and/or MGIT-960) was 3.7% (278/7,480) in the clinical samples of patients with suspected tuberculosis. The culture positivity was 3.4% for LJ (254/7,480) and 3.7% for MGIT-960 (278/7,480). The contamination rate in cultures was 9% (675/7,480) for LJ and 7% (525/7,480) for MGIT-960. In the study, all strains identified as MBTC or NTMs were identified as the same species by both methods.
During the study period, PCR assay was performed for 24 patients’ samples upon request from the ordering clinics. A commercial automated Real-time PCR assay (QIAGEN Benelux B.V. The Netherlands) was used at a reference laboratory. Out of these 24 samples, five (20.8%) were positive. PCR positive samples were also positive in liquid (MGIT-960) and solid (LJ) culture methods as studied in house, but only three were positive by AFB. One of the samples negative by PCR (19 patients) was positive by the AFB staining, and 17 out of these 19 specimens were positive on solid media (LJ); all 19 were positive in liquid (MGIT-960) culture.
Two hundred thirty-three (MTBC) and 45 (NTMs) strains were positive by liquid (MGIT-960) or solid (LJ) culture methods. NTMs distribution was as follows: 11 (24.5%) isolates were of
The most MTBC isolates were from respiratory specimens; 120 from sputum, 35 from BALs, and four from tracheal aspirates. The remaining MTBC were recovered from different specimen types. Of the total 45 isolated NTMs strains, 37 were isolated from sputum samples. The number and the types of specimens from which mycobacteria were isolated are presented in Table I.
Number, species, AFB positivity and distribution of Mycobacterial strains according to clinical samples.
AFB | MTBC | NTMs | ||
---|---|---|---|---|
Respiratory | 198 | 98 | 159 | 39 |
Sputum | 157 | 89 | 120 | 37 |
Bronchoalveolar lavage | 37 | 7 | 35 | 2 |
Tracheal aspirate | 4 | 2 | 4 | – |
Tissue | 22 | 3 | 21 | 1 |
Lymph Node Biopsy | 12 | 2 | 12 | – |
Other Tissues | 10 | 1 | 9 | 1 |
Sterile body fluid | 22 | – | 22 | – |
Pleura | 13 | – | 13 | – |
BOS | 6 | – | 6 | – |
Peritoneum | 3 | – | 3 | – |
Abscess | 18 | 3 | 17 | 1 |
Fasting gastric fluid | 11 | – | 9 | 2 |
Urine | 7 | – | 5 | 2 |
Total | 278 | 104 | 233 | 45 |
In the study, the AFB was observed in 98 respiratory patient samples. We performed AFS for the patient respiratory samples as well as the growing microorganisms in the culture. However, 198 respiratory samples grew
In all 104 patients, the AFB positive samples (respiratory, tissue, sterile body fluid), at least one type of
When the age distribution of the patients was examined, a bi-modal distribution was observed. The number of patients diagnosed with tuberculosis peaked twice between the ages of 20–31 and 60–71. Similarly, isolations of MTBC peaked twice in the patients of 20–31 and 60–71 age range. The isolation of NTMs species was also prominent in the 0–11 age range. The distribution of Mycobacterial strains according to age groups is presented in Fig. 1.
Fig. 1.
Distribution of

Of the 233 MTBC strains isolated in the study, 182 (78.1%) were susceptible to all 1st-line anti-tuberculosis drugs, while 51 isolates (21.9%) were resistant to at least one of the 1st-line anti-tuberculosis drugs tested (Table II). Total drug resistance rates for INH, SM, RIF, and ETM were 16.7% (n = 39), 14.6% (n = 34), 3% (n = 7), and 0.8% (n = 2), respectively. The highest rates of resistance were observed to the pair of INH + SM (n: 22, 9.4%), and the highest rates of resistance to three drugs were against INH + SM + RIF (n = 73%). Seven rifampin-resistant strains were also resistant to INH and SM. One of the strains was resistant to four 1st-line anti-tuberculosis drugs. In our study, the rate of MDR-TB was 13.7% (7/51) among resistant strains and 3% (7/233) among all strains isolated.
Number and proportion of resistant MTBC strains by years.
2015 | 2016 | 2017 | 2018 | 2019 | Total | ||
---|---|---|---|---|---|---|---|
Sensitive to all drugs | 11 | 42 | 49 | 61 | 19 | 182 | (78.1) |
INH | 2 | 3 | 13 | 12 | 9 | 39 | (16.7) |
SM | 2 | 1 | 11 | 12 | 8 | 34 | (14.6) |
RIF | 1 | – | 2 | 2 | 2 | 7 | (3) |
EMB | – | – | – | 1 | 1 | 2 | (0.8) |
İNH + SM | 2 | 1 | 8 | 7 | 5 | 23 | (9.9) |
INH + RIF + SM (MDR-TB) | 1 | 2 | 2 | 2 | 7 | (3) |
In the present study, 21.4% of MTBC isolates in 2015, 6.7% in 2016, 25.8% in 2017, 21.8% in 2017, 36.7% in 2018, and 36.7% in 2017 were tested against 1st-line anti-tuberculosis drugs. As the number of strains isolated in 2017 and 2018 increased, so did the number of resistant strains. However, this increase was not statistically significant (
The number of
TB remains a major public health problem throughout the world. According to the 2018 report of the World Health Organization, it was estimated that in 2017 approximately 10 million people suffered from TB, and approximately 1.5 million people have died (WHO 2019). The determination of the presence of the etiological agent and correct identifications are important to prevent the spread of tuberculosis. Therefore, it is necessary to isolate, determine the type, and to assess the drug resistance of
Direct microscopic examination of smears is rapid and relatively practical and, therefore, is preferred despite low rates of sensitivity in detecting bacilli (Kurtoglu et al. 2011). Patients positive on direct microscopic examination are considered to be both more contagious and exhibit a fast progression to clinical disease. Consequently, a direct microscopic examination is recommended, especially in patients with pulmonary tuberculosis (Tarylan et al. 2015).
In our study, the AFB positivity was 1.4% (104/7,480), and culture positivity (LJ and/or MGIT-960) was 3.7% (278/7,480) in patients with suspected tuberculosis. Overall, MTBC detection rate was 3.1% (233/7,480). Similarly, MTBC detection rate was between 2.1% and 11% in many studies (Baylan et al. 2002; Dundar et al. 2009; Kurtoglu et al. 2011).
Today, culture is the standard gold method for the detection of mycobacteria (Kunduracioglu et al. 2013). World Health Organization recommends the use of liquid media for
Age distribution of TB patients is an important parameter reflecting the control of TB in the community. While the disease peaks in advanced ages in populations that implement effective TB control programs, in populations where the control programs are lax, the disease peaks at younger ages (Karatas et al. 2019). In some studies, the TB is seen mostly in advanced ages (Coffman et al. 2017); however, in an earlier Turkish study (Karatas et al. 2019), it was reported two peaks of the TB prevalence in the age group 15–24 and over 65 years old. Similarly, we noticed that the number of patients diagnosed with tuberculosis peaked twice between the ages of 20–31 and 60–71 years. These results suggest that the Turkish population is composed of mixed communities where both loose and effective TB control efforts are exerted.
The isolation rate of mycobacteria (NTMs) other than the
In our study, NTMs were isolated from 45 patients. Among NTMs,
In many studies, it has been reported that resistance to INH and RIF are often, but resistance to other anti-tuberculosis drugs may also develop (Dheda et al. 2014; Pienar et al. 2018). However, in some studies, similar to our study, resistance to INH and SM was higher, and RIF and ETM resistances were reduced. In these studies, there were significant differences between the resistance rates by region, and the primary anti-tuberculosis drugs with the highest resistance rates were INH and SM (Kurtoglu et al. 2011; Linger et al. 2014; Sani et al. 2015; Stagg et al. 2017). It is thought that higher rates of INH and SM resistance compared to other primary anti-tuberculosis drugs may be related to the more frequent use of these drugs in both prophylaxis and treatment. Similar arguments could be put forth for this country.
The Report of the Turkish Association of Anti-TB Campaign published in 2018 indicated that in 2016, the drug susceptibility test results were surveyed for 6,037 MTC, and resistance to at least one drug was detected in 19.2% isolates. According to this report, 3.3% of the patients who underwent drug susceptibility testing were found to have MDR-TB, and the rate of multidrug resistance was 2.1% in new patients and 14.2% in previously treated patients (Saglik Bakanligi T.C. 2018). According to WHO 2018 data, MDR-TB ratio is 3.5% of new TB cases and 18% of previously treated cases globally (WHO 2019). The rates of MDR-TB in the studies made in different regions of Turkey vary between 2.2–14.7% (Saral et al. 2007; Dundar et al. 2009; Aydin et al. 2011; Kurtoglu et al. 2011). In our study, resistance to more than one drug was detected in 51 (21.88%) isolates. MDR-TB ratio was 13.7% (7/51) among resistant strains and 3% (7/233) among all strains isolated, and this rate was consistent with other studies.
Today, the number of patients with tuberculosis has increased, possibly due to changes in recent years such as social and economic turmoil, increased number of migrant patients, changes in the practices healthcare system, and drug-resistant
One of the limitations of this study was that the patients and the isolates were selected from a single centre albeit it was a large tertiary care centre. This might have influenced the information gathered. However, it should also be stated that the medical centre where the study is conducted is located in the heart of the old city of Istanbul, where the immigrants are concentrated.
Data from this study indicate that the frequency of isolations of
In conclusion, this investigation demonstrates that tuberculosis is still a growing public health threat in Istanbul, Turkey. We do not know how much of this increase is the result of the recent high immigration rates. The drug resistance rates also seem to be on the rise. Therefore, rapid and accurate laboratory services are imperative in combatting such a growing public health menace. Our study demonstrates that the liquid culture is superior to the solid media for the recovery of
Fig. 1.

Number and proportion of resistant MTBC strains by years.
2015 |
2016 |
2017 |
2018 |
2019 |
Total |
||
---|---|---|---|---|---|---|---|
Sensitive to all drugs | 11 | 42 | 49 | 61 | 19 | 182 | (78.1) |
INH | 2 | 3 | 13 | 12 | 9 | 39 | (16.7) |
SM | 2 | 1 | 11 | 12 | 8 | 34 | (14.6) |
RIF | 1 | – | 2 | 2 | 2 | 7 | (3) |
EMB | – | – | – | 1 | 1 | 2 | (0.8) |
İNH + SM | 2 | 1 | 8 | 7 | 5 | 23 | (9.9) |
INH + RIF + SM (MDR-TB) | 1 | 2 | 2 | 2 | 7 | (3) |
Number, species, AFB positivity and distribution of Mycobacterial strains according to clinical samples.
AFB | MTBC | NTMs | ||
---|---|---|---|---|
Respiratory | 198 | 98 | 159 | 39 |
Sputum | 157 | 89 | 120 | 37 |
Bronchoalveolar lavage | 37 | 7 | 35 | 2 |
Tracheal aspirate | 4 | 2 | 4 | – |
Tissue | 22 | 3 | 21 | 1 |
Lymph Node Biopsy | 12 | 2 | 12 | – |
Other Tissues | 10 | 1 | 9 | 1 |
Sterile body fluid | 22 | – | 22 | – |
Pleura | 13 | – | 13 | – |
BOS | 6 | – | 6 | – |
Peritoneum | 3 | – | 3 | – |
Abscess | 18 | 3 | 17 | 1 |
Fasting gastric fluid | 11 | – | 9 | 2 |
Urine | 7 | – | 5 | 2 |
Total | 278 | 104 | 233 | 45 |